Protara Therapeutics, Inc.
TARADrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
2
Next Catalyst
Aug 10, 2026
6dMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
TARA Earnings Report
EPS Est: $-0.33 | FQ end 2026-06
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How TARA's past catalysts played out
Choline Chloride for Injection
Choline Deficiency
TARA-002
Non-muscle Invasive Bladder Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Choline Chloride for Injection | Phase 3 | Choline Deficiency | - | - |
TARA-002 | Phase 2 | Non-muscle Invasive Bladder Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Protara Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Protara Therapeutics, Inc.'s (TARA) pipeline across Phase 3, Phase 2. Its lead program is Choline Chloride for Injection (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Protara Therapeutics, Inc.'s next FDA catalyst?→
Protara Therapeutics, Inc.'s (TARA) next tracked catalyst is a Earnings expected August 10, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TARA biotech catalysts?→
Add TARA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Protara Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.